**Core Concept**
The question is testing knowledge of pharmacological treatments for erectile dysfunction (ED) in males. ED is a condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. The underlying principle being tested involves the physiological mechanisms of penile erection and the role of nitric oxide, cyclic guanosine monophosphate (cGMP), and phosphodiesterase type 5 (PDE5) in this process.

**Why the Correct Answer is Right**
The correct answer is **sildenafil**, a phosphodiesterase type 5 (PDE5) inhibitor. Sildenafil works by inhibiting the action of PDE5, an enzyme responsible for the degradation of cGMP in the smooth muscle cells of the corpus cavernosum. This leads to increased levels of cGMP, causing smooth muscle relaxation and increased blood flow to the penis, resulting in an erection. The nitric oxide-cGMP pathway plays a crucial role in penile erection, and PDE5 inhibitors like sildenafil are effective in treating ED by enhancing this pathway.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not specified. If a specific drug was listed, it would be evaluated in the same manner as the correct answer.
* **Option B:** This is incorrect because while certain antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), can cause ED as a side effect, they are not used to treat ED specifically.
* **Option C:** This is incorrect because alpha-blockers, such as prazosin, are used to treat hypertension and benign prostatic hyperplasia (BPH), but they are not the primary treatment for ED.

**Clinical Pearl / High-Yield Fact**
PDE5 inhibitors like sildenafil are contraindicated in patients taking nitrates due to the risk of severe hypotension. This is because nitrates also cause vasodilation, which can lead to a dangerous drop in blood pressure when combined with PDE5 inhibitors.

**Correct Answer: C. Sildenafil**